Global Healthcare Company Faces Drug Diversion Allegations

We represented a global healthcare company regarding a drug diversion allegation that controlled substances were inappropriately ordered, secured and dispensed by the company in violation of state and federal law. After conducting an internal investigation into the allegations and meeting with the DEA, the government declined to pursue further action against our client.

You Also May Be Interested In:

  • Representation of ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation of licensure laws caused submission of false claims and that defendants fraudulently billed services as performed by physicians even though patients were seen only by nurse practitioners. We obtained dismissal of the licensure claims and received summary judgment as to the upcoding claims. U.S. ex rel. Taylor v. Boyko, 2020 WL 520933 (S.D. W. Va. Jan. 31, 2020); U.S. ex rel. Taylor v. Perni, 2020 WL 2499544 (S.D. W. Va. May 14, 2020).

    We serve as lead counsel representing ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation...
  • We served as lead counsel representing one the largest privately-held skilled nursing facility companies in the country in connection with...
    Client Type: Private Company
  • We served as lead counsel representing the largest independent intraoperative neuromonitoring service provider in connection with a multi-year company-wide False...
    Client Type: Private Company